{"id":"lomustine-intermediate-dose-cytarabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neurotoxicity (cytarabine-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lomustine is a lipophilic alkylating agent that cross-links DNA strands, while cytarabine at intermediate doses inhibits DNA polymerase and incorporates into DNA to disrupt replication. Together, they provide complementary cytotoxic mechanisms targeting rapidly dividing leukemic cells. This combination is typically used in acute leukemia treatment protocols.","oneSentence":"This combination uses lomustine (a nitrosourea alkylating agent) and intermediate-dose cytarabine (a nucleoside antimetabolite) to damage cancer cell DNA and inhibit DNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:20.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia (likely acute myeloid leukemia or acute lymphoblastic leukemia)"}]},"trialDetails":[{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT03609060","phase":"PHASE2","title":"Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2018-08-24","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT00925873","phase":"PHASE3","title":"GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1996-06","conditions":"Acute Myeloid Leukemia","enrollment":303},{"nctId":"NCT00700544","phase":"PHASE3","title":"Treatment Outcome in Elderly Patients","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2002-06","conditions":"AML, Elderly Patients","enrollment":330},{"nctId":"NCT00480064","phase":"PHASE3","title":"Lomustine and Intermediate Dose Cytarabine in Older Patients With AML","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1995-07","conditions":"Acute Myeloid Leukemia","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lomustine, intermediate dose cytarabine","genericName":"Lomustine, intermediate dose cytarabine","companyName":"French Innovative Leukemia Organisation","companyId":"french-innovative-leukemia-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses lomustine (a nitrosourea alkylating agent) and intermediate-dose cytarabine (a nucleoside antimetabolite) to damage cancer cell DNA and inhibit DNA synthesis. Used for Acute leukemia (likely acute myeloid leukemia or acute lymphoblastic leukemia).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}